Analysts already were asking Exelixis Inc. about the possibility of "decelerated" growth of Cabometyx (cabozantinib) as the company rolled out third-quarter results that show it doing well with the launch of the tablets, approved in April for advanced renal cell carcinoma patients who have received prior anti-angiogenic therapy.